Poster
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Tumor-agnostic
A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 immunohistochemistry 3+ solid tumors: DESTINY-PanTumor04
Bradley J. Monk
Mini-Oral
Pipeline Compounds
JSMO 2026 | March 26-28, 2026
Tumor-agnostic
DS-3939, a TA-MUC1 antibody–drug conjugate in advanced/metastatic solid tumors: Initial first-in-human results
Toshihiko Doi
Oral
HER3-DXd
JSMO 2026 | March 26-28, 2026
Tumor-agnostic
HERTHENA-PanTumor01: Expansion of a global phase 2 trial of HER3-DXd in patients with advanced/metastatic solid tumors
Izuma Nakayama
Poster
Other/Multi
ACoP16 | October 18-21, 2025
Tumor-agnostic
QSP I-O & ADCs: Integration of an antibody-drug conjugates mechanistic model into an immuno‐oncology quantitative systems pharmacology platform
Yafei Wang
Poster
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Tumor-agnostic
Trastuzumab deruxtecan for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 part 1 primary analysis
Yanqiao Zhang
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Tumor-agnostic
Trastuzumab deruxtecan for pretreated patients with HER2-expressing solid tumors: DESTINY-PanTumor02 part 1 final analysis
Vicky Makker
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Tumor-agnostic
Trastuzumab deruxtecan in pretreated patients with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 part 1
Jung-Yun Lee